📗 Cite This Artifact
TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeutic Exploitation
Score: 73/100 | MI:8 TR:7 N:7 DI:8 RE:9 CE:7 TE:8 EB:8 AU:8 TP:7
Experiment Overview
This study investigates how TMEM106B haplotypes modify FTD severity across all genetic forms (GRN, MAPT, C9orf72, sporadic). TMEM106B is the first validated genetic modifier of FTD, with protective haplotypes reducing disease severity by 4-6 years. Understanding the mechanism will enable therapeutic exploitation of protective pathways.
Hypothesis
TMEM106B protective haplotypes reduce FTD severity through:
Protective haplotypes can be mimicked with small molecules or gene therapy.
Research Gap Addressed
FTD Gap #11: Can TMEM106B haplotypes modify FTD severity regardless of primary mutation?
Validation Protocol
Phase 1: Mechanism Elucidation
Approach: Determine how TMEM106B modifies FTD pathogenesis
Model Systems:
- iPSC-derived neurons from FTD patients with protective vs risk haplotypes
- Mouse models with human TMEM106B knock-in (protective vs risk)
- Cell lines with CRISPR-edited TMEM106B
Score: 73/100 | MI:8 TR:7 N:7 DI:8 RE:9 CE:7 TE:8 EB:8 AU:8 TP:7
Experiment Overview
This study investigates how TMEM106B haplotypes modify FTD severity across all genetic forms (GRN, MAPT, C9orf72, sporadic). TMEM106B is the first validated genetic modifier of FTD, with protective haplotypes reducing disease severity by 4-6 years. Understanding the mechanism will enable therapeutic exploitation of protective pathways.
Hypothesis
TMEM106B protective haplotypes reduce FTD severity through:
Protective haplotypes can be mimicked with small molecules or gene therapy.
Research Gap Addressed
FTD Gap #11: Can TMEM106B haplotypes modify FTD severity regardless of primary mutation?
Validation Protocol
Phase 1: Mechanism Elucidation
Approach: Determine how TMEM106B modifies FTD pathogenesis
Model Systems:
- iPSC-derived neurons from FTD patients with protective vs risk haplotypes
- Mouse models with human TMEM106B knock-in (protective vs risk)
- Cell lines with CRISPR-edited TMEM106B
| Assay | What It Measures |
|-------|-----------------|
| Lysosomal pH | Functional assessment |
| Progranulin trafficking | Live cell imaging |
| TDP-43 aggregation | RT-QuIC, immunofluorescence |
| Autophagy flux | LC3, p62 turnover |
| Microglial phenotype | RNA-seq, cytokine profiling |
Phase 2: Protective Pathway Identification
Approach: Identify downstream effectors of TMEM106B protection
Screening:
- Transcriptomics: protective vs risk haplotypes
- Proteomics: pathway differences
- CRISPR screen: genes that restore protection when knocked out
- TFEB/mitophagy pathway
- Lysosomal enzyme activity
- Progranulin processing
- Neuroimmune signaling
Phase 3: Therapeutic Exploitation
Approach: Develop therapies that mimic protective TMEM106B effect
Approaches:
In vivo validation:
- FTD mouse models with protective vs risk TMEM106B
- Test therapeutic candidates for:
- Reduced TDP-43 pathology
- Improved behavioral outcomes
- Increased survival
Expected Outcomes
Timeline
| Phase | Duration | Milestone |
|-------|----------|-----------|
| Phase 1 | 18 months | Mechanism elucidated |
| Phase 2 | 12 months | Protective pathways identified |
| Phase 3 | 24 months | Therapeutic candidates validated |
Total: 54 months to preclinical candidates
Feasibility Assessment
| Factor | Score | Notes |
|--------|-------|-------|
| Technical Feasibility | 8/10 | Established models; clear hypothesis |
| Model Validity | 8/10 | Human iPSC and mouse models available |
| Timeline | 54 months | Reasonable for mechanism-to-therapy |
| Cost | $4.8M | Moderate, primarily personnel and reagents |
Cost Breakdown:
- Phase 1: $1.6M (mechanism studies)
- Phase 2: $1.2M (screening)
- Phase 3: $2.0M (therapeutic development)
Clinical Impact
- Current problem: No genetic modifiers identified for FTD therapy
- Solution: TMEM106B mechanism provides actionable target
- Benefit: ~4-6 year delay in onset for protective haplotypes
- Broader application: Platform for identifying additional modifiers
Cross-Disease Value
- TMEM106B also modifies ALS and PD
- Lysosomal pathway relevant to other neurodegenerative diseases
- Protective mechanism may apply broadly to proteinopathies
See Also
- [GRN Carrier Resilience](/experiments/grn-carrier-resilience-ftd)
- [Progranulin-TDP-43 Mechanism](/experiments/progranulin-tdp43-mechanism-ftd)
- [FTD Knowledge Gaps](/gaps/ftd)
- [Lysosomal Dysfunction in FTD](/mechanisms/ftd-lysosomal-pathway)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | experiments-tmem106b-genetic-modifier-ftd |
| kg_node_id | None |
| entity_type | experiment |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-60273d76808d |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'experiments-tmem106b-genetic-modifier-ftd'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-experiments-tmem106b-genetic-modifier-ftd?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeutic Exploitation](http://scidex.ai/artifact/wiki-experiments-tmem106b-genetic-modifier-ftd)
http://scidex.ai/artifact/wiki-experiments-tmem106b-genetic-modifier-ftd